SynAct Pharma AB (SYNACT) - Total Liabilities
Based on the latest financial reports, SynAct Pharma AB (SYNACT) has total liabilities worth Skr44.13 Million SEK (≈ $4.75 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
SynAct Pharma AB - Total Liabilities Trend (2014–2025)
This chart illustrates how SynAct Pharma AB's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of SynAct Pharma AB to evaluate short-term liquidity relative to the company's equity base.
SynAct Pharma AB Competitors by Total Liabilities
The table below lists competitors of SynAct Pharma AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jinhui Shipping and Transportation Limited
OL:JIN
|
Norway | Nkr166.22 Million |
|
Cheviot Company Limited
NSE:CHEVIOT
|
India | Rs645.38 Million |
|
Kawan Food Bhd
KLSE:7216
|
Malaysia | RM53.88 Million |
|
Jayant Agro Organics Limited
NSE:JAYAGROGN
|
India | Rs3.23 Billion |
|
Grupo Mexicano de Desarrollo S.A.B
MX:GMD
|
Mexico | MX$3.96 Billion |
|
Birla Cable Limited
NSE:BIRLACABLE
|
India | Rs1.62 Billion |
|
Demco Public Company Limited
BK:DEMCO
|
Thailand | ฿2.39 Billion |
|
Welspun Investments and Commercials Limited
NSE:WELINV
|
India | Rs909.56 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down SynAct Pharma AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SynAct Pharma AB market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SynAct Pharma AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SynAct Pharma AB (2014–2025)
The table below shows the annual total liabilities of SynAct Pharma AB from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr50.23 Million ≈ $5.41 Million |
-10.87% |
| 2024-12-31 | Skr56.35 Million ≈ $6.06 Million |
+8.72% |
| 2023-12-31 | Skr51.83 Million ≈ $5.58 Million |
+222.42% |
| 2022-12-31 | Skr16.08 Million ≈ $1.73 Million |
-8.14% |
| 2021-12-31 | Skr17.50 Million ≈ $1.88 Million |
+205.68% |
| 2020-12-31 | Skr5.72 Million ≈ $616.10K |
-44.48% |
| 2019-12-31 | Skr10.31 Million ≈ $1.11 Million |
+177.43% |
| 2018-12-31 | Skr3.72 Million ≈ $399.95K |
+60.65% |
| 2017-12-31 | Skr2.31 Million ≈ $248.97K |
-33.76% |
| 2016-12-31 | Skr3.49 Million ≈ $375.87K |
+6027.54% |
| 2015-12-31 | Skr57.00K ≈ $6.13K |
-29.63% |
| 2014-12-31 | Skr81.00K ≈ $8.72K |
-- |
About SynAct Pharma AB
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis; host targeted treatment for viral infections such as respiratory infections, dengue virus, as well as polymyalgia rheumatica (PMR); and id… Read more